Get the Daily Brief
Latest Biotech News
New lab platforms enter early access: single‑molecule proteomics and Tri‑Mod RNA assay
Nautilus Biotechnology installed its first external single‑molecule protein analysis instrument at the Buck Institute to study tau proteoforms in neurodegenerative disease, marking the company’s...
Doudna spinoff Azalea raises $82M: single‑dose in vivo CAR‑T aims for clinic
Azalea Therapeutics, a spinout from Jennifer Doudna’s lab, launched with an $82 million financing to pursue in‑body genome editing approaches that aim to convert patients’ immune cells into...
Biotech shake‑ups: billionaire‑backed Arena shutters; Colossal buys Viagen cloning arm
Arena BioWorks, a high‑profile, privately funded Boston research institute launched with $500 million, abruptly announced it will shut down operations and lay off staff, citing adverse biotech...
FDA leadership shake-up and uniQure setback: regulator turmoil delays Huntington’s gene therapy
uniQure said the FDA reversed prior guidance and no longer considers Phase I/II data using an external control adequate to support a biologics license application for AMT‑130, its gene therapy for...
Sarepta’s Duchenne confirmatory failure — company to press FDA despite negative readout
Sarepta reported that its ESSENCE Phase III confirmatory trial for two exon‑skipping antisense oligonucleotides failed to meet the primary endpoint, producing a p‑value well above the prespecified...
Metsera takeover battle heats up — Novo raises bid to $10B as Pfizer files lawsuits
Novo Nordisk boosted its takeover offer for obesity biotech Metsera to as much as $10 billion, proposing an initial cash dividend followed by contingent payments tied to development milestones....
Thermo Fisher to buy Clario for $8.8B: clinical trials data and digital push accelerates
Thermo Fisher Scientific agreed to acquire Clario for $8.8 billion to expand its clinical‑trial data, patient‑centric services, and digital capabilities within its Laboratory Products and...
Qiagen buys Parse Biosciences to jump into single‑cell genomics
Qiagen announced it will acquire Parse Biosciences for $225 million upfront plus up to $55 million in milestones, marking a strategic move into scalable single‑cell genomics. Parse’s...
Colossal acquires Viagen Pets & Equine — cloning and biobanks join de‑extinction push
Colossal Biosciences said it has acquired Viagen Pets & Equine, a cloning and reproductive services company that maintains a biobank spanning more than 40 species, including endangered animals....
Doudna‑backed Azalea launches with $82M to pursue single‑dose in‑vivo CAR‑T
Azalea Therapeutics, a spinoff from Jennifer Doudna’s lab, launched with $82 million to develop single‑dose, in‑vivo CAR‑T approaches that convert patients’ immune cells directly inside the body....
Nautilus places single‑molecule protein platform at Buck — first external install lifts stock
Nautilus Biotechnology installed its single‑molecule protein analysis system at the Buck Institute for Research on Aging as the first external customer deployment, enabling targeted studies of tau...
Arena BioWorks shutters: billionaire‑backed research institute pulls plug amid funding squeeze
Arena BioWorks, a Boston research institute launched in 2024 with $500 million from a group of billionaire backers, confirmed an abrupt shutdown after investors cited deteriorating biotech macro...
Roche pays $55M for Manifold Bio brain‑shuttle pact — $2B program to cross blood‑brain barrier
Roche signed a strategic collaboration and licensing agreement with Manifold Bio to develop next‑generation brain shuttles designed to ferry therapeutic payloads across the blood‑brain barrier....
FDA leadership crisis: CDER chief exits after misconduct probe
George Tidmarsh resigned as director of the FDA’s Center for Drug Evaluation and Research after being placed on administrative leave amid a Department of Health and Human Services probe into...
FDA reverses course on uniQure Huntington's data — submission timeline in doubt
UniQure said the FDA signaled it no longer regards data from the company’s Phase I/II AMT-130 program versus an external control as sufficient to support a Biologics License Application, throwing...
Metsera M&A melee: Novo’s $10B pitch meets Pfizer lawsuits
Metsera’s board declared Novo Nordisk’s latest proposal a superior proposal after Novo raised its bid to as much as $10 billion, setting off swift legal retaliation from Pfizer. Pfizer filed...
Sarepta confirmatory flop: Duchenne exon‑skipping trial fails primary endpoint
Sarepta Therapeutics announced its ESSENCE Phase III confirmatory trial for two exon‑skipping antisense oligonucleotides failed to meet the study’s primary endpoint, a blow to drugs marketed under...
Off‑the‑shelf CAR‑T shows promise – Caribou posts encouraging lymphoma results
Caribou Biosciences reported data suggesting its off‑the‑shelf CAR‑T candidate delivers deep, durable remissions in advanced B‑cell lymphoma, with response rates approaching benchmarks set by...
Nautilus lands at Buck Institute: single‑molecule proteomics reaches neurodegeneration labs
Nautilus Biotechnology installed its single‑molecule protein analysis platform at the Buck Institute to study tau proteoforms in Alzheimer’s and other neurodegenerative diseases. Buck is the first...
Pharmacogenomics gap widens as OneOme shutters CLIA lab
OneOme, the Mayo Clinic spinoff known for the RightMed pharmacogenomics test, announced a sudden closure of operations citing financial challenges. The Minneapolis‑based company will stop...